List of Micro-Cap Cancer Companies Listed on Major U.S. Exchanges

This list includes companies that provide cancer products and/or services with market capitalizations between 50 million dollars and 300 million dollars. In the world of investing these are referred to as micro-cap stocks. We update this page at the start of every month so it is possible that during the course of a month a company’s market cap might go below 50 million or above 300 million.

Additional cancer focused companies can be found in our cancer section. A comparison widget that shows trend, earnings per share (EPS), P/E ratio and beta for each of the companies on this list can be accessed through the link below.
Actinium Pharmaceuticals, Inc. (ATNM) (Biopharmaceutical company: immunotherapeutics for the treatment of advanced cancers)

Affimed N.V. (AFMD) (Germany, biopharmaceutical company: cancer immunotherapies)

Aileron Therapeutics, Inc. (ALRN) (IPO June 29, 2017; biopharmaceutical company: cancer)

Anavex Life Sciences Corp. (AVXL) (Biopharmaceutical company: Alzheimer’s, other CNS diseases; cancer)

ArQule, Inc. (ARQL) (Small molecule cancer therapeutics)

AVEO Pharmaceuticals, Inc. (AVEO) (Biopharmaceutical company: therapies through biomarker-driven insights)

Bio-Path Holdings, Inc. (BPTH) (Therapeutic products using its proprietary liposomal delivery technology)

BioXcel Therapeutics, Inc. (BTAI) (IPO March 8, 2018; biopharmaceutical company: neuroscience and immuno-oncology)

CASI Pharmaceuticals, Inc. (CASI) (Biopharmaceutical company: therapeutics addressing cancer and other unmet medical needs; focus on China)

Celcuity Inc. (CELC) (IPO September 20, 2017; diagnostic tests for new cancer subtypes)

Cellular Biomedicine Group, Inc. (CBMG) (Treatments for cancer and degenerative diseases)

Celyad SA (CYAD) (IPO in June 2015: Cell therapy treatments; cardiovascular disease, oncology)

Compugen Ltd. (CGEN) (Israel: immuno-oncology programs which are aimed at harnessing the immune system to eradicate cancer)

Concert Pharmaceuticals, Inc. (CNCE) (CNS disorders, renal disease, inflammation and cancer)

CTI BioPharma Corp. (CTIC) (Biopharmaceutical company: therapies covering a spectrum of blood-related cancers)

CytRx Corporation (CYTR) (Biopharmaceutical company: research and development company specializing in oncology)

Dicerna Pharmaceuticals, Inc. (DRNA) (Biopharmaceutical company: inherited diseases of the liver and genetically defined cancers)

Diffusion Pharmaceuticals Inc. (DFFN) (Cancer focused biotech company)

Endocyte, Inc. (ECYT) (Biopharmaceutical company: therapies for the treatment of cancer and inflammatory diseases)

ESSA Pharma Inc. (EPIX) (Canada: small molecule drugs for the treatment of prostate cancer)

Fate Therapeutics, Inc. (FATE) (Biopharmaceutical company: cellular immunotherapeutics; cancer, rare genetic diseases and immune disorders)

Fortress Biotech (FBIO) (Biopharmaceutical company: cancer, additional products in pipeline)

Galectin Therapeutics Inc. (GALT) (Therapies for fibrotic diseases and cancer)

Genprex, Inc. (GNPX) (IPO March 29, 2018; gene therapy: cancer)

GTX, Inc. (GTXI) (Small molecules for the treatment of cancer and serious medical conditions)

Immune Design Corp. (IMDZ) (Immunotherapy company)

ImmunoGen, Inc. (IMGN) (Targeted cancer therapeutics)

Immutep Limited (IMMP) (Immunotherapeutic products for the treatment of cancer)

Infinity Pharmaceuticals, Inc. (INFI) (Biopharmaceutical company: Blood cancers, indolent non-Hodgkin lymphoma, chronic lymphocytic leukemia)

Kura Oncology, Inc. (KURA) (IPO in November 2015: Biopharmaceutical company; therapeutics for the treatment of solid tumors and blood cancers)

Leap Therapeutics, Inc. (LPTX) (Cancer therapies)

MEI Pharma, Inc. (MEIP) (Therapies for the treatment of cancer)

Merus N.V. (MRUS) (IPO May 19, 2016, Netherlands: immuno-oncology company)

Midatech Pharma plc (MTP) (Oncology treatment and supportive care products)
Mirati Therapeutics, Inc. (MRTX) (Oncology company: genetically-targeted oncology therapeutics)

Nantkwest Inc. (NK) (IPO in June 2015: Immunotherapy company: cancer)

Oasmia Pharmaceutical AB (OASM) (IPO in October 2015, Sweden: Human and animal oncology)

Oncobiologics, Inc. (ONS) (IPO May 13, 2016, biopharmaceutical company: biosimilar therapeutics)

Pieris Pharmaceuticals, Inc. (PIRS) (Biotechnology company: areas of focus include cancer, asthma and anemia)

Regulus Therapeutics Inc. (RGLS) (Biopharmaceutical company: microRNA therapeutics for oncology indications and orphan diseases)

Rexahn Pharmaceuticals, Inc. (RNN) (Biopharmaceutical company: therapeutics for the treatment of cancer)

SELLAS Life Sciences Group, Inc. (SLS) (Biopharmaceutical company: cancer immunotherapies)

Sensus Healthcare, Inc. (SRTS) (IPO June 3, 2016: medical device company focused on skin cancers as well as other skin conditions)

Sesen Bio, Inc. (SESN) (Antibody-drug conjugate (ADC) cancer therapies)

Sorrento Therapeutics, Inc. (SRNE) (Oncology company: treatments for cancer and associated pain)

Stemline Therapeutics, Inc. (STML) (Biopharmaceutical company: therapeutics that target cancer stem cells and tumor bulk)

Sunesis Pharmaceuticals, Inc. (SNSS) (Biopharmaceutical company: oncology therapeutics for the potential treatment of solid and hematologic cancers)

Syndax Pharmaceuticals, Inc. (SNDX) (IPO March 3, 2016: Biopharmaceutical company engaged in the development of cancer treatments)

Tocagen Inc. (TOCA) (IPO April 13, 2017; cancer-selective gene therapies)

Tracon Pharmaceuticals, Inc. (TCON) (IPO in January 2015: Biopharmaceutical company: therapeutics for cancer, age-related macular degeneration and fibrotic diseases)

Trillium Therapeutics Inc. (TRIL) (Canada: immuno-oncology company)

Vascular Biogenics Ltd. (VBLT) (Israel: Treatments for cancer)

Verastem, Inc. (VSTM) (Biopharmaceutical company: drugs to treat cancer by the targeted killing of cancer stem cells)

VTV Therapeutics Inc. (VTVT) (IPO in July 2015: Clinical stage pharmaceutical company:  cancer, central nervous system disorders, diabetes and metabolic disorders, inflammation)

Zymeworks Inc. (ZYME) (IPO April 28, 2017; biopharmaceutical company: cancer)

Related Links:

List of Companies in the Healthcare Sector

List of Pharmaceutical Companies

List of Biotech Companies

List of Healthcare ETFs

List of Publicly Traded Companies